Prostate Cancer

Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.

An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.

Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).

A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.

An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.

Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.

Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.

Tanya Dorff, MD, discusses findings from a phase 1 clinical trial that explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

"Anatomic radical prostatectomy really transformed radical prostatectomy from a very morbid operation with high risk, performed rarely, to one that became a commonly utilized treatment for prostate cancer," says Christopher L. Amling, MD, FACS.

The blood-based, non-invasive IsoPSA test is used prior to an initial biopsy to assess the likelihood that a patient has high-grade prostate cancer.

"As we celebrate 50 years of successes, the Gleason grading system deserves recognition," writes Michael S. Cookson, MD, MMHC.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

“Determining the optimal balance for length of therapy is paramount,” said Ashley Ross, MD, PhD.

“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.

The sNDA is based on findings from the phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT boosted overall survival in patients with mHSPC.

Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

The final results from the phase 3 ARCHES trial showed that the addition of enzalutamide to androgen deprivation therapy also continued to improve radiologic progression-free survival and other secondary end points.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.